Published in Mol Pain on June 11, 2010
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One (2013) 0.99
Upregulation of cystathionine β-synthetase expression contributes to visceral hyperalgesia induced by heterotypic intermittent stress in rats. PLoS One (2012) 0.89
Epigenetic modification of DRG neuronal gene expression subsequent to nerve injury: etiological contribution to complex regional pain syndromes (Part I). Med Sci Monit (2014) 0.86
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol (2016) 0.85
NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain. Pharmacol Res Perspect (2015) 0.85
Reverse Regulatory Pathway (H2S / PGE2 / MMP) in Human Aortic Aneurysm and Saphenous Vein Varicosity. PLoS One (2016) 0.81
Hydrogen sulfide-induced itch requires activation of Cav3.2 T-type calcium channel in mice. Sci Rep (2015) 0.75
Hydrogen Sulfide: A Worthwhile Tool in the Design of New Multitarget Drugs. Front Chem (2017) 0.75
High glucose stimulates cell proliferation and Collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling. Int Urol Nephrol (2017) 0.75
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J (2002) 6.89
Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev (2001) 6.50
The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci (1996) 6.04
Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature (1988) 5.88
AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem (1999) 4.49
A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology (2000) 3.31
Novel neural modulators. Annu Rev Neurosci (2003) 2.91
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol (1994) 2.70
The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? J Neurochem (2004) 2.50
Visceral pain: a review of experimental studies. Pain (1990) 2.47
Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science (1995) 2.12
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A (1996) 2.03
Molecular biology of opioid receptors. Trends Neurosci (1993) 1.78
Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun (2000) 1.67
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol Sci (1995) 1.55
Phosphorylation of Ser363, Thr370, and Ser375 residues within the carboxyl tail differentially regulates mu-opioid receptor internalization. J Biol Chem (2001) 1.46
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem (2006) 1.37
mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem (1998) 1.34
Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J Neurosci (2005) 1.33
Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol (2008) 1.30
Retracted Hydrogen sulfide is produced in response to neuronal excitation. J Neurosci (2002) 1.25
Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett (1995) 1.25
Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol (2004) 1.18
The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K(+) channels. Br J Pharmacol (2000) 1.11
An opiate-receptor gene family reunion. Trends Neurosci (1994) 1.10
Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. Neuroscience (2007) 1.09
G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab (2006) 1.08
Evidence that hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function: in vitro and in vivo studies in the rat. J Neuroendocrinol (2000) 1.05
EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation. Mol Biol Cell (2008) 1.01
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain (1995) 0.99
Selective blockade of peripheral delta opioid agonist induced antinociception by intrathecal administration of delta receptor antisense oligodeoxynucleotide. Neurosci Lett (1996) 0.93
Mu-opioid receptor activation prevents apoptosis following serum withdrawal in differentiated SH-SY5Y cells and cortical neurons via phosphatidylinositol 3-kinase. Neuropharmacology (2003) 0.92
Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception. J Pharmacol Exp Ther (1997) 0.92
Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol Biochem Behav (1991) 0.90
The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. Brain Res (2001) 0.89
delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta(1) and delta(2) receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. Life Sci (2005) 0.89
Role of agonist-dependent receptor internalization in the regulation of mu opioid receptors. Neuroscience (2000) 0.88
Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil (2007) 0.87
Role of hydrogen sulfide in visceral nociception. Gut (2009) 0.87
Role of beta-arrestins in the intracellular trafficking of G-protein-coupled receptors. Adv Pharmacol (1998) 0.87
Supraspinal antinociceptive response to [D-Pen(2,5)]-enkephalin (DPDPE) is pharmacologically distinct from that to other delta-agonists in the rat. J Pharmacol Exp Ther (2000) 0.87
NPY-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. Peptides (2005) 0.86
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem (2008) 0.86
Fedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat. Neurogastroenterol Motil (2000) 0.86
Monoclonal antibody to the delta opioid receptor acts as an agonist in dual regulation of adenylate cyclase in NG108-15 cells. FEBS Lett (1999) 0.86
Nutrient ingestion increases rectal sensitivity in humans. Physiol Behav (1994) 0.84
Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. J Pharmacol Exp Ther (2003) 0.84
Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. J Pharmacol Exp Ther (2002) 0.83
Antisenses to opioid receptors attenuate ATP-gated K(+) channel opener-induced antinociception. Eur J Pharmacol (1999) 0.76
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol (2009) 1.69
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology (2006) 1.59
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol (2004) 1.52
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci (2009) 1.45
Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci (2003) 1.43
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol (2008) 1.26
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res (2009) 1.23
Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem (2006) 1.21
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. J Med Chem (2010) 1.18
PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol (2006) 1.17
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta (2010) 1.11
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One (2011) 1.11
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation (2013) 1.11
Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.11
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther (2005) 1.11
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J Med Chem (2011) 1.09
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One (2011) 1.08
Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol (2010) 1.07
Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J Med Chem (2011) 1.04
Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler Thromb Vasc Biol (2004) 1.03
VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One (2012) 1.02
Farnesoid X receptor: from structure to potential clinical applications. J Med Chem (2005) 1.02
Primary brain abscess with Nocardia farcinica in an immunocompetent patient. Clin Neurol Neurosurg (2002) 1.01
Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol (2011) 1.01
Retracted A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol (2002) 1.01
The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol (2005) 1.00
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One (2013) 0.99
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol (2009) 0.98
Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion (2002) 0.98
A magic bullet for mucosal protection...and aspirin is the trigger! Trends Pharmacol Sci (2003) 0.97
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. Diabetes (2013) 0.97
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology (2008) 0.96